Table 1.
Reported cases concerning the use of rituximab in WG patients with intestinal involvement
| Author/year of publication | Number of cases | Sex/age | Involvement | Type of bowel involvement | c-ANCA | Indication | Previous treatment | Therapy regimen | Follow-up duration |
|---|---|---|---|---|---|---|---|---|---|
| Minami et al (2007)9 | 1 | F/55 | Upper respiratory tract, eyes, lungs, bowel and neurological | Intestinal perforation | + | Refractory disease , aggressive progression | Steroid cyclophosphamide γ-globulin | 375 mg/m2/every 4 weeks Totally 4 cures | 14 months |
| Oristrellet al (2009)4 | 1 | M/73 | Upper respiratory tract, lungs, bowel, | Mesenteric ischaemia, intestinal perforation | + | Pancytopenia and infection due to cyclophosphamide , aggressive progression | Steroid cyclophosphamide | 375 mg/m2/every 4 weeks Totally 4 cures | 22 months |
| Steinbach et al (2010)9 | 1 | NA/45 | Lungs, bowel, kidney | Paralitic ileus, haemorrhagic necrosis | + | Aggressive progression | Steroid cyclophosphamide | Rituximab Dosage: NA | NA |
| Witsch et al (2011)10 | 1 | F/70 | Lungs, bowel, neurological, kidney | Intestinal haemorrhagy, ileo-caecal involvement | + | Aggressive progression | Steroid plasmapheresis γ-globulin | 375 mg/m2/every 4 weeks totally 4 cures | NA |